Skip to content

Local Treatment by Thermic Destruction of Primitive Breast Cancer

Local Treatment by Thermic Destruction of Primitive Breast Cancer. Phase II: Feasibility and Effectiveness, Standardization of Procedures.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01706016
Acronym
LASERBREAST1
Enrollment
16
Registered
2012-10-15
Start date
2012-10-09
Completion date
2016-11-17
Last updated
2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Demonstrate the effectiveness of laser in the treatment of cancerous lesions by determinating with histological analysis of the specimen the percentage of tumor cells remaining in the area treated by the laser

Interventions

PROCEDUREThermic destruction of tissue by Laser using the Novilase device

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Noninflammatory unilateral and unifocal breast cancer * Size \</= 20mm (ultrasound measure) * Histological confirmation of cancer by biopsy grade status hormone and HER2. * Good delineation of the lesion on ultrasound. * Minimum distance of 5 mm between the tumor and the skin between the tumor and muscle. * Age between 18 and 80 * ECOG performance status 0 or 1

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness of laser treatment28 days after initial diagnosisDestruction of the carcinoma will be assess by histological analysis of the specimen. If more than 10% of viables cancerous cells are remaining in the volume treated by laser, the procedure would be a fail

Secondary

MeasureTime frameDescription
Life qualityD-0 and before the surgeryLife quality will be assess using the questionnaire QLQ-C30 breast module BR23-version 3

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026